A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study
暂无分享,去创建一个
R. van Oerle | H. Grundt | D. Pritchard | A. Larsen | H. Cate | J. Govers-Riemslag | V. Pönitz | T. Brügger-Andersen | R. Oerle | D. W. Nilsen | Patrycja Næsgaard | Hugo ten Cate
[1] H. Staines,et al. Activated factor XII type A predicts long‐term mortality in patients admitted with chest pain 1 , 2009, Journal of thrombosis and haemostasis : JTH.
[2] B. Boehm,et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk , 2008, Journal of thrombosis and haemostasis : JTH.
[3] C. Hack,et al. The plasma kallikrein–kinin system and risk of cardiovascular disease in men , 2007, Journal of thrombosis and haemostasis : JTH.
[4] R. Jaffe,et al. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. , 2007, Journal of the American College of Cardiology.
[5] B. Jilma,et al. Evidence of a U‐shaped association between factor XII activity and overall survival , 2007, Journal of thrombosis and haemostasis : JTH.
[6] StéphaneCook,et al. Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation , 2007 .
[7] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[8] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[9] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[10] Frits R Rosendaal,et al. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. , 2006, Blood.
[11] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[12] T. Melberg,et al. Late complications following the deployment of drug eluting stents. , 2006, International journal of cardiology.
[13] K. Kent,et al. Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents , 2006, Circulation.
[14] T. Renné,et al. Defective thrombus formation in mice lacking coagulation factor XII , 2005, The Journal of experimental medicine.
[15] F. Eberli,et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. , 2005, European heart journal.
[16] Giuseppe Musumeci,et al. Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.
[17] H. Fagertun,et al. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. , 2004, American heart journal.
[18] Jacqueline P Mitchell,et al. Comparison of Novel Hemostatic Factors and Conventional Risk Factors for Prediction of Coronary Heart Disease , 2000, Circulation.
[19] G. Miller,et al. Epidemiological and Genetic Associations of Activated Factor XII Concentration With Factor VII Activity, Fibrinopeptide A Concentration, and Risk of Coronary Heart Disease in Men , 2000, Circulation.
[20] R. Colman,et al. Thrombin and Human Plasma Kallikrein Inhibition during Simulated Extracorporeal Circulation Block Platelet and Neutrophil Activation , 1998, Thrombosis and Haemostasis.
[21] J. Cooper,et al. Risk of coronary heart disease and activation of factor XII in middle-aged men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[22] Z. Toossi,et al. Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. Colman,et al. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. , 1986, Blood.
[24] J. Dunn,et al. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. , 1983, The Journal of clinical investigation.
[25] K. Fujikawa,et al. Mechanism of activation of bovine factor XI by factor XII and factor XIIa. , 1980, Biochemistry.
[26] K. Austen,et al. A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1971, The Journal of experimental medicine.
[27] R. van Oerle,et al. A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. , 2010, Thrombosis journal.
[28] G. Panic,et al. [Late stent thrombosis]. , 2009, Medicinski pregled.
[29] P. Keeling,et al. The dinoflagellates Durinskia baltica and Kryptoperidinium foliaceum retain functionally overlapping mitochondria from two evolutionarily distinct lineages , 2007, BMC Evolutionary Biology.
[30] G. Miller,et al. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor. , 2000, Thrombosis and haemostasis.
[31] A. Carter,et al. Levels of Activated FXII in Survivors of Myocardial Infarction – Association with Circulating Risk Factors and Extent of Coronary Artery Disease , 1998, Thrombosis and Haemostasis.
[32] G. Murano. The “Hageman” connection: Interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation , 1978, American journal of hematology.
[33] R. Colman,et al. Activation of bovine factor VII by hageman factor fragments. , 1977, Blood.